Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
Cognitive impairment associated with schizophrenia predicts poor functional outcomes. Currently, no approved pharmacotherapy is available. This study...
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide. The primary endpoint was the overall mean...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
